Objective: This analysis examined the effectiveness of utilizing interferon-gamma release assay (IGRA) technology in a TB (TB) screening program at a university.
Participants: Participants were 2299 students at a Montana university who had presented to the university health center for TB screening during 2012 and 2013.
Methods: A retrospective study was conducted utilizing data from student health center medical records. Time and financial expenditures were determined, and the cost of the present screening process and 2 alternative scenarios was calculated.
Results: The current process is the most costly and time-consuming scenario for TB testing. Testing exclusively with IGRAs is the least labor-intensive for staff and creates revenue, whereas a dual method, utilizing IGRAs for high-risk students and skin tests for others, provides a solution that better responds to the demographic of the population.
Conclusions: This assessment shows that IGRAs are a cost-effective tool for screening a global student population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/07448481.2014.1003378 | DOI Listing |
BMC Infect Dis
January 2025
The Third Department of Infection, Fifth Hospital of Shijiazhuang, Shijiazhuang, Hebei, China.
Background: The common diagnostic methods for tuberculosis have been showing reduced sensitivity among chronic obstructive pulmonary disease patients. This study was conducted to evaluate and analyse the diagnostic value of an interferon-γ release assay in COPD patients complicated with pulmonary tuberculosis.
Methods: A nested case-control study was conducted on 123 COPD patients hospitalized at the Fifth Hospital of Shijiazhuang, Hebei Province, from January 2019 to June 2021.
Front Immunol
January 2025
Department of Medical Immunology, Medical University of Gdansk, Gdansk, Poland.
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease, characterized by impaired wound repair, tissue remodeling and fibrosis. Immune system may participate in the development and progression of the disease as indicated by altered activity in IPF sufferers. This study investigates the immune response to the BNT162b2 COVID-19 vaccine in patients with IPF compared to healthy controls, with a particular focus on evaluation of antibody responses, interferon-gamma release, cytokine profiling and a broad panel of immune cell subpopulations.
View Article and Find Full Text PDFClin Exp Dermatol
January 2025
Department of Dermatology, University of Virginia, Charlottesville, Virginia, USA.
Hidradenitis suppurativa (HS) patients treated with tumor necrosis factor (TNF) inhibitors are at an increased risk for tuberculosis (TB) reactivation, necessitating baseline latent TB infection (LTBI) screening. However, evidence regarding the value of periodic LTBI screening in this population is limited. In this single-center retrospective chart review, we investigated the LTBI rate in HS patients treated with adalimumab or infliximab.
View Article and Find Full Text PDFInfection
January 2025
Department of Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Parkallee 35, Borstel, Germany.
Purpose: Deciding whether to provide preventive treatment to contacts of individuals with multidrug-resistant (MDR) tuberculosis is complex.
Methods: We present the diagnostic pathways, clinical course and outcome of tuberculosis treatment in eight siblings from a single family. Tuberculosis disease was diagnosed by Mycobacterium tuberculosis culture and molecular detection of M.
Arch Public Health
January 2025
Chongqing Municipal Institute of Tuberculosis, Chongqing, 400045, China.
Background: Previous research has indicated a low tuberculin skin tests (TST) strong positive rate in school tuberculosis (TB) screening implemented by community-level medical and health care institutions in China. The research objective was to evaluate the latent tuberculosis infection (LTBI) detection gap in school contact investigation in China.
Methods: In this cross-sectional study, school contacts were investigated by Chongqing Municipal Institute of Tuberculosis between January 2022 and April 2024 in Chongqing, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!